- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Advanced PD-L1 Positive Malignancies
Total 570 results
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast CarcinomaUnited States
-
Alison StopeckEli Lilly and Company; AstraZenecaWithdrawnLocally Advanced Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer FemaleUnited States
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerUnited States, Korea, Republic of, Australia, Hong Kong, Taiwan, Malaysia, Thailand, Argentina, Belgium, Portugal
-
Peking UniversityUnknownHER2 Positive Advanced Gastric CancerChina
-
Kymera Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Acute Lymphocytic Leukemia | Lymphomas | Myeloid MalignanciesUnited States
-
Novartis PharmaceuticalsCompletedEstrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA GeneUnited States, Netherlands, Spain, Germany, United Kingdom
-
AGO Study GroupPhilipps University Marburg Medical Center; medac GmbHCompletedRadio/Chemotherapy in Node Positive Advanced Vulvar CancerGermany
-
Shanghai Miracogen Inc.RecruitingLocally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction CancerChina
-
University of UtahPfizerCompletedAdvanced KRAS Positive Metastatic Colorectal CancerUnited States
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingHER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction AdenocarcinomaAustria, Belgium, Germany, Italy
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingMetastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast CancervUnited States
-
The First Affiliated Hospital of Zhengzhou UniversityBeiGene; Jiangsu Hengrui Pharmaceutical Co., Ltd.; RemeGen Co., Ltd.Not yet recruitingHER2-positive or Mutated Advanced Colorectal Cancer
-
DualityBio Inc.RecruitingHER2-positive Advanced Solid TumorChina, United States, Australia, Puerto Rico
-
MedSIRPfizerCompletedBreast Cancer | Advanced Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of BreastSpain, Germany, France, United Kingdom, Italy, Slovenia
-
Cancer Trials IrelandTerminatedMetastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast CancerIreland, Spain
-
M.D. Anderson Cancer CenterCompleted
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditionsUnited States
-
Mirati Therapeutics Inc.TerminatedAdvanced Malignancies, Non-small Cell Lung CancerUnited States
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
University of Milano BicoccaRecruitingAdvanced Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerItaly
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Yale UniversityMerck Sharp & Dohme LLCRecruitingPembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaMelanoma | Renal Cell Carcinoma | Metastatic Melanoma | Brain Metastases | Pembrolizumab | Lenvatinib | PD1/PD-L1 ExperiencedUnited States
-
Century Therapeutics, Inc.RecruitingAggressive Non-Hodgkin Lymphoma | R/R CD19-Positive B-Cell Malignancies | Indolent Non-Hodgkin LymphomaUnited States
-
Nanfang Hospital of Southern Medical UniversityXiangya Hospital of Central South University; Tongji Hospital; Guangzhou First... and other collaboratorsCompletedChronic Myeloid Leukemia | Acute Leukemia | Myelodysplastic SyndromeChina
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
MedImmune LLCCompletedKidney Cancer | Clear Cell Renal Cell Carcinoma | Select Advanced MalignanciesUnited States, France, Canada, United Kingdom, Netherlands, Australia
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
-
Reshma L. Mahtani, D.O.Gilead SciencesNot yet recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Hormone-receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Low Breast CancerUnited States
-
Changhai HospitalUTC Therapeutics Inc.RecruitingCD70-positive Advanced Urologic NeoplasmsChina
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast CarcinomaUnited States
-
Blueprint Medicines CorporationRecruitingAdvanced Systemic MastocytosisUnited States, Norway, Netherlands, Belgium, Germany, France, Spain
-
AHS Cancer Control AlbertaCross Cancer InstituteTerminatedNon-small Cell Lung Cancer | Advanced Solid MalignanciesCanada
-
AstraZenecaCompletedNon-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,Japan
-
Consorzio OncotechClinical Research Technology S.r.l.UnknownBreast Cancer | Metastatic Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Locally Advanced Malignant NeoplasmItaly
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
University Hospital, AkershusVestre Viken Hospital Trust; NovartisRecruitingBreast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast CancerNorway
-
Icahn School of Medicine at Mount SinaiActive, not recruitingLocally Advanced HPV Positive Oropharynx CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedAdvanced, Androgen Receptor Positive Triple Negative Breast CancerUnited States, Spain, Belgium, Canada, Ireland, United Kingdom, Italy
-
Rush University Medical CenterCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Myeloid MalignanciesUnited States
-
University of Illinois at ChicagoCompletedIntensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (IM-TMI)Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Lymphoblastic Leukemia | Non Hodgkins LymphomaUnited States
-
Mayo ClinicRecruitingMultiple Myeloma | Myelodysplastic Syndrome | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Hematopoietic and Lymphoid System Neoplasm | Advanced Lung Carcinoma | Advanced Prostate Carcinoma | Advanced Glioblastoma | Advanced Gastric Carcinoma | Advanced Breast Carcinoma | Advanced Colorectal... and other conditionsUnited States
-
AstraZenecaCompletedPart A and B: Advanced Solid Malignancies | Part C: Malignant MesotheliomaJapan
-
Relay Therapeutics, Inc.Active, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA MutationUnited States
-
OncoTherapy Science, Inc.TerminatedAML | Advanced MDS | ALL | Advanced CML | Advanced MPNsUnited States
-
Hackensack Meridian HealthTerminatedMyeloproliferative Disorders | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloid MalignanciesUnited States
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Lei LiUnknownCamrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine CarcinomasChemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 AntibodyChina
-
iCell Gene TherapeuticsThe General Hospital of Western Theater Command; Peking University Shenzhen... and other collaboratorsRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative NeoplasmChina